|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues: | |||||
| Revenue from development agreement | |||||
| Revenue from license agreement | |||||
| Option to license revenue | |||||
| Revenue from purchase agreement | |||||
| Revenue from option agreement | |||||
| Total revenues | |||||
| Cost and expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Impairment loss | |||||
| Loss from operations | |||||
| Other income, net | |||||
| Interest income | |||||
| Gain from settlement of account payable | |||||
| Total other income, net | |||||
| Net loss from continuing operations | |||||
| Gain from discontinued operations | |||||
| Gain from insurance recovery | |||||
| Net loss | |||||
| Other comprehensive loss: | |||||
| Foreign currency translation adjustment loss | |||||
| Comprehensive loss | |||||
| Net loss per share from continuing operations - basic | |||||
| Net gain per share from discontinued operations - baisc | |||||
| Net loss per share - Basic | |||||
| Net loss per share - Diluted | |||||
| Weighted average shares used in calculating: | |||||
| Basic shares | |||||
| Diluted shares | |||||
Loading...